Analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to announce $5.25 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Kala Pharmaceuticals’ earnings. The highest sales estimate is $6.50 million and the lowest is $4.27 million. The company is scheduled to report its next quarterly earnings report on Monday, March 9th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year sales of $12.35 million for the current fiscal year, with estimates ranging from $10.91 million to $14.40 million. For the next financial year, analysts anticipate that the firm will report sales of $59.56 million, with estimates ranging from $35.08 million to $94.71 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The firm had revenue of $1.45 million during the quarter, compared to analyst estimates of $3.56 million.
Kala Pharmaceuticals stock traded up $0.40 during mid-day trading on Thursday, hitting $4.11. The company’s stock had a trading volume of 374,000 shares, compared to its average volume of 249,192. The firm has a market capitalization of $126.17 million, a PE ratio of -1.66 and a beta of 2.13. The stock’s fifty day moving average is $3.84 and its two-hundred day moving average is $5.11. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16. Kala Pharmaceuticals has a 1 year low of $3.24 and a 1 year high of $9.25.
Several hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in shares of Kala Pharmaceuticals by 20.3% during the second quarter. BlackRock Inc. now owns 1,684,802 shares of the company’s stock worth $10,749,000 after purchasing an additional 283,747 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kala Pharmaceuticals by 25.1% during the second quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock worth $7,896,000 after purchasing an additional 248,287 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Kala Pharmaceuticals by 4.9% during the second quarter. Northern Trust Corp now owns 198,260 shares of the company’s stock worth $1,265,000 after purchasing an additional 9,183 shares during the last quarter. Boston Partners grew its holdings in shares of Kala Pharmaceuticals by 542.6% during the second quarter. Boston Partners now owns 118,431 shares of the company’s stock worth $756,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Wedbush Securities Inc. grew its holdings in shares of Kala Pharmaceuticals by 163.9% during the third quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock worth $340,000 after purchasing an additional 55,410 shares during the last quarter. 68.84% of the stock is currently owned by institutional investors.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.